Why Is Hyoscyamine Not FDA Approved?

Hyoscyamine has never gone through FDA approval because it didn’t have to. The drug was already on the market before the United States created the modern regulatory system requiring proof of safety and efficacy, so it was effectively grandfathered in. It has been prescribed for decades to treat gastrointestinal cramping, irritable bowel syndrome, and other conditions, all while existing in a regulatory gray zone that most patients and even some prescribers don’t fully appreciate. The story behind that gray zone involves a quirk of twentieth-century lawmaking, a slow-moving federal enforcement effort, and a pharmaceutical industry with little financial incentive to change the status quo.

The Pre-1938 Loophole

Before 1938, drug manufacturers in the United States could sell products without demonstrating to the government that those products were safe. The Federal Food, Drug, and Cosmetic Act of 1938 changed that by requiring evidence of safety before a new drug could reach the market. Then, in 1962, the Kefauver-Harris Amendment added a second requirement: manufacturers also had to prove their drugs actually worked. But neither law was applied retroactively to drugs already being sold. If a product was on pharmacy shelves before 1938, it could stay there without ever proving safety or efficacy under the new rules.

Hyoscyamine, an alkaloid derived from plants in the nightshade family, falls squarely into this category. It was used in medicine long before modern clinical trials existed. A study examining pre-1938 medications found that out of 88 formulations of 59 drugs that had been marketed before the 1938 Act, only 3 had obtained FDA approval before the 1962 efficacy requirement took effect, and just 14 more were approved afterward.¹ The vast majority of these older drugs, hyoscyamine among them, simply continued to be sold without anyone formally establishing that they met modern standards.

This wasn’t an accident or an oversight. The FDA’s resources were focused on evaluating new drugs entering the market, not on retroactively reviewing everything already available. For decades, these legacy products existed in a kind of regulatory limbo: not approved, not banned, just present.

Why Manufacturers Never Pursued Approval

Getting FDA approval is expensive. Running the clinical trials, compiling the required safety data, and navigating the regulatory process can cost tens or hundreds of millions of dollars. For a drug like hyoscyamine, that investment makes almost no business sense. The compound is not patentable. It is a naturally occurring molecule that has been known for well over a century, which means any company that invested in gaining FDA approval would be handing the benefit to every competitor who could then reference that approval to sell their own generic version.

There’s also no market pressure pushing for approval. Physicians have been prescribing hyoscyamine for gastrointestinal complaints for decades, and insurers have been covering it. Patients fill the prescription, use the drug, and most of them never think to ask whether it carries a formal FDA stamp. The practical distinction between “FDA-approved” and “marketed without FDA approval” is invisible at the pharmacy counter. Without a patent to protect, without a market gap to fill, and without a regulatory demand to comply, no manufacturer has had a compelling reason to spend the money.

The FDA’s Unapproved Drugs Initiative

In 2006, the FDA acknowledged that the ongoing sale of unapproved drugs was a public health problem and launched its Unapproved Drugs Initiative, sometimes called the UDI. The goal was straightforward: push manufacturers of these legacy products to either obtain proper approval or pull their drugs from the market. In practice, this played out unevenly.

Between 2006 and 2015, 34 previously unapproved prescription drugs were targeted by the initiative. The results were mixed. Among the 26 drugs where pricing data was available, the average wholesale price rose by a median of 37% in the two years following either voluntary approval or an enforcement action, and the range was dramatic, with some drugs seeing price increases exceeding 200%. Drug shortages also became more common: the proportion of targeted drugs experiencing shortages rose from 50% to about 74% after the initiative acted on them.²

This pattern created an awkward dynamic. When the FDA did enforce against an unapproved drug, the remaining manufacturer that bothered to get approval often became the sole supplier and raised prices accordingly. Critics argued that the initiative, while well-intentioned, punished patients by driving up costs and reducing availability of inexpensive medications that had long track records of use. Supporters countered that “long track record” is not the same as “proven safe and effective,” and that formal review catches problems that informal experience misses. Hyoscyamine has not been a primary target of the UDI to date, but the initiative’s existence hangs over every unapproved legacy drug, and the practical consequences of enforcement have made the whole category a politically charged subject.

What the Clinical Evidence Actually Shows

Here is where things get uncomfortable for hyoscyamine’s defenders: the formal evidence base is thin. Hyoscyamine is an anticholinergic drug, meaning it works by blocking a chemical messenger called acetylcholine in the nervous system. This relaxes smooth muscle in the gut, which is why it’s prescribed for cramping, spasms, and the urgency associated with irritable bowel syndrome. The pharmacological mechanism is well understood. What’s less clear is how well it performs in rigorous, controlled studies compared to other options.

A systematic review of randomized controlled trials for irritable bowel syndrome found that smooth-muscle relaxants as a class showed the strongest evidence for relieving abdominal pain as the predominant symptom.³ But that review examined smooth-muscle relaxants broadly, not hyoscyamine specifically. Much of the evidence for the class comes from drugs like dicyclomine (which is FDA-approved) and agents available in Europe that aren’t sold in the U.S. Hyoscyamine itself has remarkably little high-quality trial data dedicated to it as an individual compound.

A retrospective study looking at irritable pouch syndrome, a condition affecting patients who have had surgery for ulcerative colitis, compared hyoscyamine extended-release to dicyclomine and desipramine. For patients with high bowel frequency, clinical improvement was seen in about 69% of those treated with hyoscyamine ER, compared to 65% for dicyclomine and 64% for desipramine. For abdominal pain specifically, hyoscyamine ER showed improvement in about 62% of treatment courses, while dicyclomine came in at 68% and desipramine at 76%. Long-term persistence, meaning patients still taking the drug after three or more years, was lowest for hyoscyamine ER at around 38%, compared to about 49% for dicyclomine.⁴

These numbers suggest hyoscyamine works reasonably well for some patients, but they also show it isn’t clearly better than alternatives that have gone through formal approval. And this was a retrospective chart review, not a randomized controlled trial, which is exactly the kind of evidence gap that the FDA approval process is designed to fill. The drug has been used for so long that its clinical reputation rests heavily on accumulated clinical experience rather than the gold-standard trial data that newer medications are required to produce.

Safety Concerns That Formal Review Might Have Caught

The lack of formal approval doesn’t mean hyoscyamine is dangerous for most adults who take it as directed. But the absence of the systematic safety review that accompanies FDA approval means there are gaps in our understanding of its risks, particularly in vulnerable populations.

One area where this has caused real harm is in infants. Hyoscyamine drops were sometimes prescribed for colic, and case reports have documented anticholinergic poisoning in babies who received the drug. Symptoms included irritability, rapid heart rate, and flushed skin, which are classic signs of anticholinergic toxicity.⁵ For a drug that never went through the rigorous dose-finding and safety studies required for FDA approval in pediatric populations, this is the kind of problem that might have been identified and labeled more prominently if formal review had ever taken place.

In older adults, anticholinergic drugs as a class have come under increasing scrutiny. These medications are linked to confusion, falls, urinary retention, dry mouth, constipation, and blurred vision. Geriatric prescribing guidelines, including the American Geriatrics Society’s Beers Criteria, flag anticholinergic drugs as potentially inappropriate for older patients. There is also a growing body of research linking long-term anticholinergic use to increased risk of cognitive decline and dementia, though the strength of that association and whether it is causal remain subjects of active debate. Hyoscyamine, as an anticholinergic, carries all of these class-level concerns, but without the drug-specific safety profile that formal approval would produce.

FDA-Approved Alternatives for IBS

If your doctor wants to prescribe something for irritable bowel syndrome that has actually cleared the FDA’s approval bar, the options depend on your subtype. For IBS with diarrhea, the FDA has approved rifaximin (a nonsystemic antibiotic), eluxadoline (which acts on opioid receptors in the gut), and alosetron (a serotonin receptor blocker, though alosetron is restricted to women with severe symptoms who haven’t responded to other treatments).⁶ For IBS with constipation, there are FDA-approved options like linaclotide and lubiprostone.

Dicyclomine, another anticholinergic antispasmodic, is FDA-approved and works through a similar mechanism to hyoscyamine. It is often prescribed for the same symptoms. When clinicians reach for hyoscyamine instead, it’s usually because of familiarity, because a patient has responded well to it in the past, or because the specific formulation (sublingual tablets, for instance, which dissolve under the tongue for faster onset) suits the patient’s needs. But from a regulatory standpoint, dicyclomine has something hyoscyamine doesn’t: formal acknowledgment that the evidence supports its use.

The broader treatment landscape for IBS now includes antidepressants at low doses, newer gut-targeted agents, dietary approaches like the low-FODMAP diet, and behavioral therapies.⁷ Hyoscyamine remains widely used alongside these options, but its position in treatment guidelines has weakened as FDA-approved alternatives with more rigorous evidence have entered the market.

What “Unapproved” Actually Means at the Pharmacy

One of the most confusing aspects of hyoscyamine’s status is that you can still get it with a prescription. “Not FDA-approved” does not mean “illegal to prescribe” or “pulled from the market.” It means the drug has not undergone the formal review process that would establish its safety and efficacy to the agency’s standards. Your pharmacist can fill the prescription. Your insurance may cover it. The drug is manufactured by companies that follow current good manufacturing practices. It looks and feels exactly like any other prescription medication.

This creates a communication gap. Patients reasonably assume that if a drug is prescribed by their doctor and dispensed by a pharmacy, it has been vetted by the FDA. That assumption is wrong in this case, but almost nobody is going out of their way to correct it. The drug’s labeling doesn’t carry the same FDA-mandated structure that approved drugs have, but unless you know what to look for, you wouldn’t notice the difference.

For prescribers, the situation is also more nuanced than it appears. Physicians can legally prescribe unapproved drugs, and many do so with confidence based on long clinical experience. But the absence of FDA approval means there is no FDA-reviewed prescribing information, no standardized package insert with the same rigor as an approved drug’s label, and no formal post-marketing surveillance system collecting adverse event data in a structured way. If something goes wrong, the safety net that exists for approved drugs is thinner.

The Economics of Legacy Drugs

The hyoscyamine situation illuminates a broader tension in American pharmaceutical regulation. There are dozens of drugs still sold in the United States that predate the modern approval framework. Some are obscure compounding ingredients. Others, like hyoscyamine, are prescribed millions of times a year. The FDA has stated its intent to address these products, but doing so creates real tradeoffs.

When enforcement actions under the Unapproved Drugs Initiative have removed competitors from the market, the remaining manufacturer frequently raises prices. Patients who relied on cheap, unapproved generics suddenly face much higher costs for the newly approved version of the same drug, or find that their medication is in shortage because fewer companies are making it.² The median price hike of 37% observed across targeted drugs is the middle of the range; some drugs saw prices multiply several times over.

This leaves regulators in a difficult position. The scientific argument for requiring formal approval is strong: patients deserve to know that the drugs they take have been rigorously evaluated. But the economic consequences of enforcement can directly harm the patients the policy is meant to protect. For a drug like hyoscyamine, which is inexpensive, widely available, and generally well-tolerated in adults, the calculus is especially tricky. The benefit of formal approval would be a more complete safety and efficacy profile. The cost could be higher prices, reduced access, and market consolidation. So far, the FDA has not forced the issue with hyoscyamine, and there is no public indication that it plans to soon.

Anticholinergic Burden and Cognitive Risk

Beyond the regulatory question, there is a clinical conversation happening around hyoscyamine that has nothing to do with its FDA status and everything to do with its drug class. Anticholinergic medications collectively contribute to what researchers call “anticholinergic burden,” a cumulative exposure that increases when a patient takes multiple drugs with anticholinergic properties or takes them for a long time.

Many common medications have some anticholinergic activity, including certain antihistamines, bladder medications, and antidepressants. When hyoscyamine is added on top of these, the total anticholinergic load can climb to levels associated with meaningful side effects, especially in older adults. The short-term effects (dry mouth, constipation, blurred vision) are annoying but manageable. The longer-term concern, supported by large observational studies though not yet definitively proven, is a possible link between sustained high anticholinergic burden and increased risk of dementia.

This concern applies to the entire class, not to hyoscyamine alone. But because hyoscyamine lacks an FDA-reviewed label with standardized warnings about this risk, and because it sits in that unusual regulatory category where oversight is lighter, patients taking it may be less likely to receive a clear conversation about anticholinergic burden than they would with an FDA-approved anticholinergic that carries explicit label warnings. The drug’s regulatory status and its clinical risk profile intersect in ways that can leave patients under-informed.